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Background: Pseudomonas aeruginosa is one of the primary pathogens isolated more fre-
quently in cystic fibrosis (CF) and it exhibits innate resistance to a wide range of antibiotics.
Purpose: We sought to determine whether the highly prevalent genotypes of P. aeruginosa are 
specifically linked to CF patients and have any related multidrug antibiotic resistance. Isolates 
from hospitalized non-CF patients and from environmental sources were also genotypically 
analyzed.
Methods: Collections of P. aeruginosa from lower respiratory secretions (n=45) were 
genotyped using pulsed-field gel electrophoresis (PFGE). Phenotypic screening for antibiotic 
susceptibility was performed for the common antimicrobial agents by E-test and automated 
Phoenix method.
Results: P. aeruginosa isolates from CF (n=32), hospitalized non-CF patients (n=13), and envi-
ronment sources (n=5) were analyzed. The population structure of P. aeruginosa is highly diverse 
and population-specific. All PFGE results of P. aeruginosa isolates fall among four major  clusters. 
Cluster 1 contained 16 P. aeruginosa isolates from CF patients and two from environmental 
sources; cluster 2 contained 11 P. aeruginosa isolates from CF and one each from non-CF and 
environmental sources; cluster 3 contained 12 P. aeruginosa isolates from hospitalized non-CF 
patients and two P. aeruginosa isolates from one CF patient and one environmental source; 
and cluster 4 consisted of three isolates from CF patients and one from the environment. The 
majority of multidrug-resistant P. aeruginosa isolates were in clusters 3 and 4. P. aeruginosa 
isolates from CF patients were resistant to ciprofloxacin (34.4%) followed by resistance to 
amikacin and gentamicin (each 28%), whereas the majority of isolates from non-CF patients 
were resistant to meropenem (69%) and were grouped in cluster 3.
Conclusion: PFGE of P. aeruginosa isolates from CF patients shows a high degree of similarity, 
suggesting specific adaptation of these clones to CF-affected lungs. The hospitalized non-CF 
cluster has a different clonal origin, indicating specific clustering in a specific location, sug-
gesting hospital-acquired P. aeruginosa infections.
Keywords: cystic fibrosis, drug susceptibility testing, Pseudomonas aeruginosa, pulsed-field 
gel electrophoresis
Introduction
Pseudomonas aeruginosa is the main bacterial pathogen that infects the lungs of 
patients with cystic fibrosis (CF).1 CF patients chronically infected with P. aeruginosa 
show a greater loss of lung function and a higher overall morbidity and mortality in 
comparison with patients with intermittent or no colonization.1–4
Initial pulmonary infection with P. aeruginosa in CF is thought to occur through 
the acquisition of unique environmental strains of P. aeruginosa, which persist and 
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undergo phenotypic changes over time in the lungs of CF 
patients.5 However, P. aeruginosa can spread between people 
with CF.6 Some so-called transmissible or epidemic strains 
are associated with a worse clinical outcome and can be 
associated with a more rapid annual loss of lung function, 
worse nutritional status, and even an increased rate of death 
or lung transplantation.7 An outbreak of colistin-resistant 
P. aeruginosa in a UK pediatric CF clinic was reported, 
describing the transmission of a genotypically indistin-
guishable P. aeruginosa strain between three patients in a 
nosocomial setting.8
Typing of strains of P. aeruginosa is important for spe-
cific characterization of the species, the choice of antibiotic 
regimen, the detection of unusual traits, and the recognition 
of a potential cluster of a single clone within patients.9
Several comprehensive molecular typing techniques 
for discriminating among P. aeruginosa strains have been 
developed, based either on DNA banding patterns such as 
restriction fragment length polymorphism and pulsed-field 
gel electrophoresis (PFGE), DNA sequencing (eg, multilo-
cus sequence typing and genome sequencing), or on DNA 
hybridization (DNA macro- and microarrays).10 PFGE typing 
is considered a common genotyping method for P. aerugi-
nosa fingerprinting and is sometimes mentioned as the gold 
standard method for this bacterium, useful for hospital epi-
demiologists who need to monitor the effectiveness of infec-
tion control measures.11–13 A recent study by Waters et al14 
demonstrated the highest level of concordance between PFGE 
and multilocus sequence typing results during the genotyp-
ing of a blinded sample of well-characterized P. aeruginosa 
isolates from CF patients across multiple  laboratories. The 
aim of this study is to determine whether the highly preva-
lent genotypes of P. aeruginosa are specifically linked to CF 
patients and related to multidrug antibiotic resistance. Isolates 
from hospitalized non-CF patients and environment sources 
were also genotypically analyzed.
Materials and methods
Patients and sampling
Sputum samples or deep-pharyngeal swabs were prospec-
tively collected and cultured over a period of 6 months from 
CF patients attending the CF clinic or hospitalized at the 
Hamad Medical Corporation, Doha, Qatar. The diagnosis 
of CF was based on one or more clinical features consis-
tent with CF, positive family history of CF in siblings and 
close relatives, elevated sweat chloride (.60 mmol/L) 
on two separate occasions, in addition to the presence of 
two disease-causing mutations in the CFTR gene. Patients 
with P. aeruginosa isolates cultured from sputum or deep-
pharyngeal swab samples were enrolled in the study (18 CF 
patients with chronic P. aeruginosa and 3 CF patients with 
intermittent P. aeruginosa infections). Chronic P. aeruginosa 
infection was defined as persistent presence of P. aeruginosa 
for at least 6 consecutive months.15 P. aeruginosa isolates 
from the lower respiratory secretions of hospitalized non-CF 
patients during the same period and P. aeruginosa isolates 
from environmental samples obtained from a water basin 
were also included in the study.
Sputum samples or deep-pharyngeal swabs from patients 
not producing sputum were inoculated onto MacConkey 
agar, Columbia blood agar, and Columbia chocolate agar 
(Mast Diagnostics Ltd, Bootle, UK). Blood and choco-
late agar media were incubated in a 5% CO
2
 atmosphere. 
After 24 hours of incubation at 37°C, lactose-negative and 
oxidase-positive colonies were selected from among the 
different colony morphology types – mucoid, nonmucoid, 
and characteristic-pigment-producing colonies – subcultured 
on 5% Columbia sheep blood agar, and identified up to the 
species level using the Phoenix 100 (Becton, Dickinson and 
Co, Franklin Lakes, NJ, USA). Mucoid colonies were further 
confirmed by growth on nutrient agar, including a control 
reference P. aeruginosa strain at 42°C. Phenotypically dif-
ferent isolates were preserved in cryotubes at −70°C until 
analysis. This study was reviewed and approved by the local 
ethics committee at Hamad Medical Corporation (number 
13103/13).
PFGE analysis
PFGE was performed according to a previously described 
protocol.16 PulseNet standard Salmonella enterica serovar 
Braenderup H9812 strain was used for running the gels in 
accordance with the PulseNet protocol.17 Two S. enterica 
serovar Braenderup H9812 precast plugs were digested with 
50 IU of XbaI restriction enzyme (isolated from Xanthomonas 
badrii) alongside Pseudomonas plugs and loaded on the gel 
in the first and sixth lanes in order to normalize for analysis 
using BioNumerics software (Applied Maths, Sint-Martens-
Latem, Belgium).
The electrophoresis was performed with the Bio-Rad 
CHEF-DR III system (Bio-Rad Laboratories Inc, Hercules, 
CA, USA). Electrophoresis run conditions were designed for 
a run time of 19 hours with 14°C cooling. The CHEF-DR 
III apparatus was then programmed to initial switch time 
2.2 seconds, final switch time 54.2 seconds, gradient 6 V, and 
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an angle of 120°. All other parameters remained identical 
with those of the standard procedure.
Following electrophoresis, the gels were stained for 
45 minutes in 600 mL of sterile distilled water containing 
50 µL of ethidium bromide (10 mg/mL) and destained in 
three washes of 30 minutes each in 600 mL of distilled water. 
The gels were analyzed using a gel documentation system 
(Bio-Rad) and saved as TIFF (tagged-image file format) 
files for further analysis. The same TIFF files were later 
imported to the BioNumerics software version 6.0 (Applied 
Maths). All the software settings were used as defaults, and 
the gel was analyzed to generate a dendrogram describing 
the relationship among the pulsotypes.
Drug susceptibility testing
Drug susceptibility testing and interpretation were performed 
according to Clinical and Laboratory Standards Institute 
guidelines using the E-test and the automated Phoenix method 
for nine antimicrobial agents, including amikacin, gentamicin, 
ceftazidime, cefepime, ciprofloxacin, imipenem, meropenem, 
piperacillin/tazobactam, and colistin. P.  aeruginosa ATCC 
27853 was used as a control.
Results
This study included 21 CF patients – 14 males and 7 females – 
from 15 families, with a median age of 15 years (range: 
4–36 years). Thirteen CF families with CFTR I1234V mutation, 
belonging to a single large Arab kindred tribe, and constituted of 
two families with three CF siblings and two families with two 
CF siblings were enrolled. The remaining families contributed 
one sibling each. Three closely related families were cousins 
to each other. Two CF patients had mutations other than CFTR 
I1234V. Furthermore, 13 CF patients provided one respiratory 
sample, six CF patients gave two samples each, one CF patient 
had three samples, and one CF patient provided four samples in 
different periods of time. Six CF patients were hospitalized for 
acute chest exacerbation during the study period. Hospitalized 
non-CF patients included two patients on mechanical ventila-
tion support, one with tracheostomy and the other with chest 
infections.
All the P. aeruginosa strains were isolated from 45 speci-
mens (41 sputum samples and four deep-pharyngeal swabs) 
and five environmental sources over a 6-month period of the 
study. P. aeruginosa isolates from CF (n=32), hospitalized 
non-CF patients (n=13), and environment sources (n=5) 
were analyzed. All P. aeruginosa isolates were successfully 
typed by PFGE, and the clusters of isolates obtained thereby 
are illustrated in the resulting dendogram (Figure 1). The 
population structure of P. aeruginosa is highly diverse and 
population-specific. PFGE analysis showed that the levels of 
genetic variation within P. aeruginosa were different among 
different clusters, with genetic relatedness within the same 
cluster. All PFGE results of P. aeruginosa isolates fall among 
four major clusters. Cluster 1 contained 16 P. aeruginosa iso-
lates from CF patients and two from environmental sources; 
cluster 2 contained 11 P. aeruginosa isolates from CF and 
one each from non-CF and environmental sources; cluster 3 
contained 12 P. aeruginosa isolates from hospitalized non-CF 
patients and two P. aeruginosa isolates from one CF patient 
and one environmental source; and cluster 4 consisted of 
three isolates from CF patients and one from the environment 
(Table 1). P. aeruginosa isolates from one CF family with 
three siblings were displayed in cluster 1, two CF families 
with siblings and closely related patients had P. aeruginosa 
isolates displayed within PFGE cluster 2, and one CF fam-
ily with two siblings having two respiratory samples had P. 
aeruginosa isolates displayed within PFGE clusters 2 and 4. 
The PFGE analysis of one CF patient with four respiratory 
samples showed genetic variation of P. aeruginosa, which was 
distributed in PFGE clusters 1 and 2 during different periods. 
One CF patient hospitalized with acute chest exacerbation, 
in whom both mucoid and nonmucoid P. aeruginosa isolates 
were evaluated, showed highly close genetic relatedness to 
hospitalized non-CF P. aeruginosa isolates in cluster 3.
P. aeruginosas isolates from CF patients showed high 
susceptibility to antipseudomonal agents and relatively low 
rates of antimicrobial resistance (Table 2). P. aeruginosa 
strains in CF patients were resistant to ciprofloxacin (34.4%), 
followed by resistance to amikacin and gentamicin (each 
28%), whereas the majority of isolates from non-CF patients 
were resistant to meropenem (69%), followed by resistance 
to ciprofloxacin (30.7%), amikacin, and gentamicin (each 
23%) and were grouped in cluster 3 (Table 1). None of the 
CF isolates were resistant to meropenem. The majority of 
multidrug-resistant P. aeruginosa (MRPA) samples were in 
clusters 3 and 4. Two CF siblings with advanced lung disease 
had the same P. aeruginosa multidrug resistance to fluoroqui-
nolones, amikacin, gentamicin, and cefepime and were within 
the same cluster 4, indicating high P. aeruginosa genetic 
relatedness. Another CF patient with advanced lung disease 
had similar multidrug resistance to antipseudomonal agents 
in his four sputum samples over the 6-month period, with the 
samples clustered in two different clusters, ie,  clusters 1 and 
2, upon PFGE analysis for P. aeruginosa.
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Figure 1 Dendrogram based on percentage similarities among P. aeruginosa isolates obtained using PFGE fingerprinting.
Abbreviations: P. aeruginosa, Pseudomonas aeruginosa; PFGE, pulsed-field gel electrophoresis; XbaI, restriction enzyme isolated from Xanthomonas badrii.
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Table 1 Number of P. aeruginosa isolates and their respective clusters on PFGE typing
Patient 
number
Source of  
P. aeruginosa
Number of  
P. aeruginosa  
isolates per patient
Cluster 1:  
CF (n=16) and  
environment  
(n=2)
Cluster 2:  
CF (n=11), non-CF  
(n=1), and environment  
(n=1)
Cluster 3:  
CF (n=2), non-CF  
(n=12), and environment  
(n=1)
Cluster 4:  
CF (n=3) and 
environment 
(n=1)
 1 cF 4 2 2
 2 cF 1 1
 3 cF 1 1
 4 cF 1 1
 5 cF 2 1 1
 6 cF 2 1 1
 7 cF 2 2
 8 cF 2 2
 9 cF 1 1
 10 cF 1 1
 11 cF 1 1
 12 cF 1 1
 13 cF 1 1
 14 cF 1 1
 15 cF 1 1
 16 cF 3 1 2
 17 cF 1 1
 18 cF 1 1
 19 cF 2 1 1
 20 cF 2 1 1
 21 cF 1 1
 22 non-cF 1 1
 23 non-cF 1 1
 24 non-cF 1 1
 25 non-cF 1 1
 26 non-cF 1 1
 27 non-cF 1 1
 28 non-cF 1 1
 29 non-cF 1 1
 30 non-cF 1 1
 31 non-cF 1 1
 32 non-cF 1 1
 33 non-cF 1 1
 34 non-cF 1 1
Environmental isolate number
 1 environment 1 1
 2 environment 1 1
 3 environment 1 1
 4 environment 1 1
 5 environment 1 1
Abbreviations: P. aeruginosa, Pseudomonas aeruginosa; PFGE, pulsed-field gel electrophoresis; CF, cystic fibrosis.
Discussion
P. aeruginosa is ubiquitous in the environment, the principal 
respiratory pathogen in CF patients, and continues to be 
the principal cause of morbidity and mortality among CF 
patients. P. aeruginosa colonization and infection may either 
be community acquired or health care associated. We identi-
fied a considerable genetic heterogeneity of P. aeruginosa in 
our patient population, and this study demonstrates a unique 
cohort of CF and hospitalized non-CF patients from a single 
center, by exploring the genetic relatedness of P. aeruginosa 
isolates from respiratory secretion using PFGE, which is 
capable of discriminating between genotypes of different 
P. aeruginosa isolates.
Interestingly, P. aeruginosa isolates from siblings of CF 
families were displayed within one PFGE cluster, suggesting 
that cross-transmission of P. aeruginosa among CF patients 
occurs more frequently when contact is more intense, especially 
among siblings. The ability of P. aeruginosa to be transmitted 
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Table 2 Number of P. aeruginosa isolates resistant to common antimicrobial agents in vitro and their respective clusters after PFGE typing
Antibiotics Distribution of resistant P. aeruginosa – PFGE clusters*
Cluster 1:  
CF resistance  
(n=6/16)
Cluster 2:  
CF resistance  
(n=5/11)
Cluster 3:  
CF resistance (n=2/2)  
and non-CF resistance  
(n=8/12)
Cluster 4:  
CF resistance 
(n=3/3)
Ciprofloxacin 3 4 6 2
amikacin 2 4 4 2
gentamicin 2 4 4 2
cefepime 1 1 2 1
Ceftazidime 0 0 2 1
Meropenem/imipenem 0 0 8 (non-cF) 0
Piperacillin/tazobactam 0 0 1 0
colistin 1 0 0 0
Note: *some isolates resistant to $2 antibiotics.
Abbreviations: P. aeruginosa, Pseudomonas aeruginosa; PFGE, pulsed-field gel electrophoresis; CF, cystic fibrosis.
from person to person with CF has been recognized as early 
as the 1980s.18–26 By employing amplified fragment-length 
polymorphism molecular fingerprinting, a previous study has 
shown similar distribution of P. aeruginosa isolates among 
siblings and closely related families, indicating person-to-
person transmission of P. aeruginosa within the same family 
or infection of P. aeruginosa possibly acquired from common 
environmental exposure.26 The PFGE of P. aeruginosa isolates 
was largely in agreement with the diversity found by ampli-
fied fragment-length polymorphism fingerprinting in several 
previous studies that showed that siblings with CF frequently 
carry identical P. aeruginosa isolates.18,27–29
One hospitalized CF patient with advanced lung disease 
had high similarity of genetic relatedness of both mucoid 
and nonmucoid P. aeruginosa isolates to the samples from 
hospitalized non-CF patients in cluster 3 indicating specific 
clustering in the specific location and suggesting hospital-
acquired P. aeruginosa infection.
There were variations of the different clusters of 
P. aeruginosa among CF patients having more than one sample 
in different periods of time. These findings were similar to pre-
viously published studies demonstrating that the predominant 
clone of P. aeruginosa would vary over time, with one clone 
predominating in one period and another clone  predominating 
in another period. This event suggests that P. aeruginosa 
infection of the CF patient’s lung is a very dynamic process, 
as proposed by Renders et al.30 P. aeruginosas isolates from 
CF patients showed high susceptibility to antipseudomonal 
agents and relatively low rates of antimicrobial resistance. 
 Fluoroquinolones are the only available antibiotics for oral 
treatment of P. aeruginosa infections. However, P.  aeruginosa 
easily becomes resistant to these drugs as we found in 31% 
among the CF  population, followed by development of 
 resistance to amikacin and gentamicin (each 24%). However, 
the carbapenems (imipenem and meropenem) remained very 
active against CF P. aeruginosa isolates, with susceptibil-
ity rates of 100%, whereas the majority of P. aeruginosa 
isolates from hospitalized non-CF patients were resistant to 
meropenem (69%) and were grouped in cluster 3; they were 
probably acquired from the hospital environment.
MRPA is a common respiratory pathogen found in 
CF patients, which routinely leads to chronic pulmonary 
infections.31,32 Multiple antibiotic-resistant P. aeruginosa 
is more likely to be a marker of more severe disease and 
more intensive therapy and is less likely to be contributing 
independently to more rapid lung function decline.33 In the 
present study, P. aeruginosa isolates from CF siblings with 
advanced lung disease and MRPA isolates had similar genetic 
relatedness on PFGE and were found within the same cluster, 
suggesting the transmission even of MRPA isolates among 
CF siblings. Clustering of P. aeruginosa isolate from another 
CF patient with advanced lung disease and MRPA isolates in 
different PFGE clusters 1, 2, and 4 suggests that the coloniz-
ing strain may occasionally be changed.
Polymyxin B sulfate and colistimethate, a prodrug of 
colistin, are administered to CF patients intravenously or by 
inhalation. Resistance to colistin has been rarely reported in 
CF patients, and there is potential for an emerging resistant 
strain.34 In the present study, we found that P. aeruginosa from 
one CF patient with a non-CFTR I1234V mutation showed 
in vitro resistance to colistin although the patient did not 
receive either nebulized or intravenous colistin.
We concluded that cross-transmission is probably com-
mon among CF siblings even with MRPA isolates. In addi-
tion, the presence of several isolates in the same patient with 
distinct genotypes suggests that the colonizing strain may 
occasionally be changed. Different patient populations have 
different PFGE clusters and different drug susceptibilities.
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